ETF Holdings Breakdown of ANIP

Stock NameANI Pharmaceuticals Inc
TickerANIP(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS00182C1036
LEI5493000T6CXTND40YH31

News associated with ANIP

MetLife Investment Management LLC Has $630,000 Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
MetLife Investment Management LLC increased its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 6.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,397 shares of the specialty pharmaceutical company’s stock after buying an additional 675 […] - 2025-05-05 09:01:03
Dimensional Fund Advisors LP Raises Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
Dimensional Fund Advisors LP raised its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 4.6% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 685,730 shares of the specialty pharmaceutical company’s stock after purchasing an additional 30,420 […] - 2025-05-05 08:20:53
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Recommendation of “Buy” from Analysts
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) has been given an average rating of “Buy” by the nine analysts that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to […] - 2025-05-01 05:12:50
Legal & General Group Plc Acquires 2,585 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
Legal & General Group Plc increased its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 5.6% during the fourth quarter, Holdings Channel.com reports. The fund owned 48,425 shares of the specialty pharmaceutical company’s stock after purchasing an additional 2,585 shares during the quarter. Legal & General Group Plc’s holdings in ANI […] - 2025-04-24 08:18:54
Invesco Ltd. Lowers Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
Invesco Ltd. lowered its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 10.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 197,545 shares of the specialty pharmaceutical company’s stock after selling 22,814 shares during the quarter. Invesco […] - 2025-04-23 08:08:58
ANI Pharmaceuticals (NASDAQ:ANIP) Stock Price Expected to Rise, Truist Financial Analyst Says
ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) had its target price upped by analysts at Truist Financial from $62.00 to $65.00 in a report released on Monday,Benzinga reports. The brokerage currently has a “hold” rating on the specialty pharmaceutical company’s stock. Truist Financial’s price target points to a potential downside of 5.73% from the company’s […] - 2025-04-23 05:42:48
Vanguard Group Inc. Sells 33,739 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
Vanguard Group Inc. reduced its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 2.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,314,372 shares of the specialty pharmaceutical company’s stock after selling 33,739 shares during the quarter. Vanguard […] - 2025-04-11 07:52:47
ANI Pharmaceuticals (NASDAQ:ANIP) Stock Rating Lowered by StockNews.com
ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a research note issued to investors on Tuesday. Other equities analysts have also recently issued reports about the stock. Leerink Partnrs raised shares of ANI Pharmaceuticals to a “strong-buy” rating in a research note on […] - 2025-04-10 06:13:02
Brokerages Set ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) PT at $79.75
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) has received a consensus rating of “Buy” from the nine brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the company. The […] - 2025-04-09 05:04:49
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Position Trimmed by Corebridge Financial Inc.
Corebridge Financial Inc. reduced its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 7.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 9,778 shares of the specialty pharmaceutical company’s stock after selling 762 shares during the quarter. Corebridge […] - 2025-04-08 07:27:01
Thrivent Financial for Lutherans Reduces Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
Thrivent Financial for Lutherans trimmed its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 1.5% in the 4th quarter, HoldingsChannel reports. The firm owned 12,828 shares of the specialty pharmaceutical company’s stock after selling 200 shares during the quarter. Thrivent Financial for Lutherans’ holdings in ANI Pharmaceuticals were worth $709,000 as of its […] - 2025-04-03 07:16:46
ANI Pharmaceuticals (NASDAQ:ANIP) Now Covered by Analysts at Jefferies Financial Group
Jefferies Financial Group initiated coverage on shares of ANI Pharmaceuticals (NASDAQ:ANIP – Free Report) in a report released on Friday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $80.00 target price on the specialty pharmaceutical company’s stock. Several other analysts have also recently commented on ANIP. StockNews.com cut shares of ANI […] - 2025-03-17 06:26:54
JPMorgan Chase & Co. Begins Coverage on ANI Pharmaceuticals (NASDAQ:ANIP)
JPMorgan Chase & Co. started coverage on shares of ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) in a research report issued to clients and investors on Wednesday, MarketBeat.com reports. The brokerage set an “overweight” rating and a $85.00 price target on the specialty pharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective would suggest a […] - 2025-03-14 06:34:45
Illinois Municipal Retirement Fund Decreases Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
Illinois Municipal Retirement Fund lowered its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 8.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 8,533 shares of the specialty pharmaceutical company’s stock after selling 799 shares during the quarter. Illinois Municipal Retirement Fund’s […] - 2025-03-05 10:46:59
ANI Pharmaceuticals (NASDAQ:ANIP) Cut to Sell at StockNews.com
StockNews.com downgraded shares of ANI Pharmaceuticals (NASDAQ:ANIP – Free Report) from a hold rating to a sell rating in a report released on Monday morning. ANIP has been the subject of several other research reports. Leerink Partners assumed coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, December 11th. They set an […] - 2025-03-04 06:50:49
Brokerages Set ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Price Target at $77.71
Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) have been given an average rating of “Buy” by the eight research firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation, six have given a buy recommendation and one has assigned a strong buy […] - 2025-02-18 06:13:03
abrdn plc Takes $13.16 Million Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
abrdn plc bought a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 237,965 shares of the specialty pharmaceutical company’s stock, valued at approximately $13,155,000. abrdn plc owned about 1.13% of […] - 2025-02-08 08:54:48
ANI Pharmaceuticals (NASDAQ:ANIP) Upgraded by StockNews.com to “Hold” Rating
ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) was upgraded by investment analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Wednesday. A number of other equities research analysts have also commented on ANIP. Truist Financial upped their price objective on shares of ANI Pharmaceuticals from […] - 2025-02-07 06:54:59
Exchange Traded Concepts LLC Has $684,000 Stock Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
Exchange Traded Concepts LLC boosted its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 2.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 12,366 shares of the specialty pharmaceutical company’s stock after acquiring an additional 310 shares during the quarter. […] - 2025-01-30 08:53:06

ANIP institutional holdings

The following institutional investment holdings of ANIP have been identified

Date ETF ISIN/Name Num Shares Book value
2025-05-08 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 14,141USD 1,011,506 1.0%
2025-05-08 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 981USD 70,171 1.0%
2025-05-08 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 10,523USD 752,710
2025-05-08 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 10,523USD 752,710 1.0%
2024-11-12 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 62USD 3,782
Total =36,230 USD 2,590,879
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.